Hsbc Holdings PLC Buys Shares of 125,482 Xencor, Inc. $XNCR

Key Points

• Hsbc Holdings PLC acquired 125,482 Xencor shares in the second quarter, valued at approximately $2.08 million and representing a 0.17% stake.
• Xencor reported better-than-expected quarterly results, with an adjusted loss of $0.29 per share versus estimates of $0.80 and revenue of $51.22 million, up 17.4% year over year.
• Analyst sentiment is mixed: five analysts rate the stock Buy, three Hold, and one Sell. The consensus rating is Hold, with an average price target of $24.86, below the reported share price of $26.06.

Hsbc Holdings PLC acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 125,482 shares of the biopharmaceutical company's stock, valued at approximately $2,083,000. Hsbc Holdings PLC owned 0.17% of Xencor as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in XNCR. AQR Capital Management LLC bought a new position in shares of Xencor during the first quarter worth $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Xencor by 9.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company's stock valued at $471,000 after buying an additional 3,692 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Xencor by 89.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock valued at $7,732,000 after buying an additional 344,088 shares in the last quarter. Creative Planning lifted its holdings in Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company's stock worth $143,000 after acquiring an additional 3,661 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Xencor by 170.9% during the second quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company's stock worth $2,594,000 after acquiring an additional 208,182 shares in the last quarter.

Xencor Price Performance

Xencor stock opened at $26.06 on Monday. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -12.01 and a beta of 0.85. The firm has a 50-day moving average of $19.80 and a 200-day moving average of $14.79. Xencor, Inc. has a one year low of $7.83 and a one year high of $30.61.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The business had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. During the same quarter in the previous year, the business earned ($0.41) earnings per share. Xencor's quarterly revenue was up 17.4% on a year-over-year basis. As a group, sell-side analysts expect that Xencor, Inc. will post -3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on XNCR shares. Wedbush increased their price target on Xencor from $26.00 to $30.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. Wall Street Zen raised Xencor from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 8th. Royal Bank Of Canada raised their target price on shares of Xencor from $19.00 to $20.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of Xencor from $13.00 to $14.00 and gave the company a "neutral" rating in a research note on Monday, May 11th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Xencor in a report on Wednesday, June 24th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xencor presently has an average rating of "Hold" and an average price target of $24.86.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.